Market capitalization | $585.82m |
Enterprise Value | $351.85m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 21.02 |
P/S ratio (TTM) P/S ratio | 35.00 |
P/B ratio (TTM) P/B ratio | 2.52 |
Revenue growth (TTM) Revenue growth | 81.04% |
Revenue (TTM) Revenue | $16.74m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
10 Analysts have issued a Stoke Therapeutics Inc forecast:
10 Analysts have issued a Stoke Therapeutics Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 17 17 |
81%
81%
|
|
Gross Profit | 12 12 |
166%
166%
|
|
EBITDA | -113 -113 |
5%
5%
|
EBIT (Operating Income) EBIT | -117 -117 |
4%
4%
|
Net Profit | -105 -105 |
2%
2%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues, including the central nervous system, eye, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.
Head office | United States |
CEO | Edward Kaye |
Employees | 110 |
Founded | 2014 |
Website | www.stoketherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.